Keywords
Arthropathies
Arthritis
Antirheumatic Agents
Amazon Region
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To characterize the lipid profile of patients with inflammatory arthropathies and to assess the influence of antirheumatic treatment on lipid parameters. Methods: A retrospective cohort study was conducted based on the analysis of 244 medical records, of which 86 were selected for data collection. Statistical analysis was performed using Bioestat 5.0 software, considering a significance level of p < 0.05 and a 95% confidence interval. Results: The sample was predominantly female (82.6%), aged over 60 years (47.7%), with a high prevalence of comorbidities (79.1%). The most frequent diagnoses were rheumatoid arthritis, systemic lupus erythematosus, and psoriatic arthritis. The prevalence of dyslipidemia increased from 53.5% to 57.0%. Analysis of lipid parameters showed a reduction in total cholesterol, an increase in HDL-c, and a decrease in both LDL-c and triglycerides. Methotrexate was the most commonly used treatment (57%). Conclusion: Adequate therapeutic management contributes to clinical remission or to a significant reduction in inflammatory activity, as evidenced in the literature, which may lower cardiovascular risk, particularly in patients with rheumatoid arthritis and psoriatic arthritis. These findings highlight the importance of systematic screening and early intervention for dyslipidemia, in parallel with antirheumatic therapy and the promotion of healthy lifestyle habits.
References
AARAMAA HK, et al. Risk of cardiovascular comorbidities before and after the onset of rheumatic diseases. Semin Arthritis Rheum. 2024;65:152382.
AMINIFAR E, et al. The pleiotropic effects of statins in rheumatoid arthritis. J Pharm Pharmacol. 2023;75(7):910-920.
BARBER MRW, et al. Global epidemiology of systemic lupus erythematosus. Nat Rev Rheumatol. 2021;17(9):515-532.
BENINCA AMA, et al. Perfil lipídico de pacientes com artrite reumatoide em uso de anti-TNF-alfa. BioSCIENCE. 2024;82:e00018.
BERG IJ, PROVAN SA. Inflammatory joint diseases and risk of cardiovascular disease in modern rheumatology. J Rheumatol. 2021;48(3):311-320.
BRANDÃO PLKO, et al. Estudo comparativo das doenças inflamatórias articulares espondilite anquilosante e artrite reumatóide. Braz Appl Sci Rev. 2020;4(4):2258-2268.
COBURN BW, et al. Association of cardiovascular outcomes with low-dose glucocorticoid prescription in patients with rheumatoid arthritis. Arthritis Rheumatol. 2024;76(11):1585-1593.
DROSOS AA, et al. Exploring Cardiovascular Risk Factors and Atherosclerosis in Rheumatoid Arthritis. Eur Jl Intern Med. 2024;128:1-9.
DROSOS GC, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81(6):768-779.
DUAN L, et al. Rheumatoid arthritis and hypothyroidism: a bidirectional Mendelian randomization study. Front Immunol. 2023;14:1146261.
FALUDI AA, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose. Arq Bras Cardiol. 2017;109(2 Suppl 1):1-76.
FERREIRA VP, et al. O colesterol HDL enquanto fator de prognóstico no doente crítico. Rev Soc Port Med Interna. 2015;22(4):199-202.
FITZGERALD O, et al. Psoriatic arthritis. Nat Ver Dis Primers. 2021;7(1):59.
GIOLLO A, et al. Cardiovascular outcomes of patients with rheumatoid arthritis prescribed disease modifying anti-rheumatic drugs: a review. Expert Opin Drug Saf. 2018;17(7):697-708.
GUŁA Z, et al. A comparison of comorbidities and their risk factors prevalence across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis with focus on cardiovascular diseases: data from a single center real-world cohort. Rheumatol Int. 2024;44:2817-2828.
MAHMOUDI M, et al. New insights to the mechanisms underlying atherosclerosis in rheumatoid arthritis. Int J Rheum Dis. 2017;20(3):287-297.
MARIANI FM, et al. Pathogenesis of rheumatoid arthritis: one year in review 2023. Clin Exp Rheumatol. 2023;41(9):1725-1734.
MONTES D, et al. Utilisation of cardiovascular preventive services in a rheumatoid arthritis cohort. RMD Open. 2023;9(4):e003318.
NAVARRO-MILLÁN I, et al. Lipid management among individuals with inflammatory arthritis in the national REasons for Geographic And Racial Differences in Stroke (REGARDS) cohort. J Int Med Res. 2018;46(1):62-69.
PAPPAN N, et al. Dyslipidemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
PB J, KERKAR PG. Management of dyslipidemia in special groups. Indian Heart J. 2024;76(Suppl 1):S96-100.
RADU A-F, BUNGAU SG. Management of Rheumatoid Arthritis: An Overview. Cells. 2021;10(11):2857.
ROBINSON G, et al. Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. J Clin Invest. 2022;132(2):e148552.
RODRIGUES WDR, et al. Lipid profile of pediatric patients with chronic rheumatic diseases - a retrospective analysis. Rev Assoc Med Bras. 2020;66(8):1093-1099.
SIEBEL CONTI E, et al. Artrite reumatoide e risco cardiovascular: revisão de literatura. Rev Corpus Hippocraticum. 2021;1(1).
VENETSANOPOULOU AI, et al. Epidemiology and Risk Factors for Rheumatoid Arthritis Development. Mediterr J Rheumatol. 2023;34(4):404-413.
VICENTE GNS, et al. Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study. Adv Rheumatol. 2021;61(1):38.
WILKINSON MJ, SHAPIRO MD. Immune-Mediated Inflammatory Diseases, Dyslipidemia, and Cardiovascular Risk: A Complex Interplay. Arterioscler Thromb Vasc Biol. 2024;44(12):2396-2406.
XAVIER HT. Características clínicas, perfil lipídico e inflamatório de pacientes com artrite reumatoide submetidos a avaliação cardiológica. Unisanta Health Science. 2024;8(2):178-184.
YAN J, et al. Dyslipidemia in rheumatoid arthritis: the possible mechanisms. Front Immunol. 2023;14:1254753.
ZHANG G, et al. Causal relationships between rheumatism and dyslipidemia: A two-sample Mendelian randomization study. Front Endocrinol. 2022;13:961505.